Posted by Michael Wonder on 20 Aug 2018
Evolus granted approval of DWP-450 by Health Canada
17 August 2018 - Evolus today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows seen at maximum frown) in adult patients under 65 years of age.
The first marketing approval for Evolus’ DWP-450 product candidate represents a major milestone achievement for the company.
Evolus will market DWP-450 in Canada through its partner Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables to hospitals, aesthetic clinics and private medical practices.
